From: The effect of calcineurin inhibitors on anthropometric measurements in kidney transplant recipients
Lipid parameters | CsA group | Tac group |
---|---|---|
Total-cholesterol | Mo 6: WrC (r: 0.272, p = 0.037) | Mo 12: WaC (r: 0.267, p = 0.030), HC (r: 0.339, p = 0.005) |
Mo 36: WaC (r: 0.339, p = 0.011) | ||
HDL-cholesterol | Mo 1: W (r: 0.330, p = 0.011), BMI (r: 0.331, p = 0.011) | - |
Mo 3: W (r: 0.274, p = 0.040), BMI (r: 0.274, p = 0.040), WrC (r: 0.277, p = 0.037) | ||
Mo 24: WaC (r: -0.272, p = 0.035) | ||
Mo 36: WHR (r: -0.287, p = 0.032) | ||
Mo 48: WrC (r: -0.291, p = 0.035) | ||
Triglyceride | Mo 6: W (r: 0.319, p = 0.014), BMI (r: 0.319, p = 0.014), BF% (r: 0.411, p = 0.001) | Mo 12: W (r: 0.369, p = 0.002), BMI (r: 0.369, p = 0.002), WaC (r: 0.246, p = 0.047), HC (r: 0.316, p = 0.010), BF% (r: 0.265, p = 0.032) |
Mo 24: WHR (r: 0.270, p = 0.037), WrC (r: 0.327, p = 0.011), NC (r: 0.308, p = 0.017) | Mo 36: BF% (r: 0.269, p = 0.047) | |
Mo 36: NC (r: 0.326, p = 0.014) | ||
Mo 48: NC (r: 0.277, p = 0.043) | ||
LDL-cholesterol | Mo 6: WrC (r: 0.262, p = 0.045), NC (r: 0.308, p = 0.018) | Mo 1: BF% (r: -0.261, p = 0.034) |
Mo 36: WaC (r: 0.276, p = 0.039), NC (r: 0.398, p = 0.002) |